Wave Life Sciences
WVE
3.54
+0.02
+0.57%
Wave Life Sciences
US · WVE
#3515 by market cap
Listed 2015
3.54
+0.02
+0.57%
Live - 5344 symbols - heartbeat 305s ago
· 2026-10-08 09:02
Pre-market
3.54
0.00%
After-hours
3.54
-0.06%
- Market cap
- 697.55M
- P/E (TTM)i
- -3.28
- P/Bi
- 1.54
- EPSi
- -1.21
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on WVE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.1 percentage points.
Institutional ownership
- Held by institutions
- 99.87% -3.13pp
- Institutions
- 287 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund40.04%
Hedge Fund25.90%
VC/PE Fund24.38%
Public Company7.60%
Private Company1.32%
Individual/Insider0.41%
Government Pension Fund0.25%
Insurance Company0.23%
Family Office/Trust0.13%
Top holders as of 2026-08-11
RA Capital Management, L.P.
13.69% · 26.98M sh
BlackRock
9.75% · 19.20M sh
GSK Equity Investments, Limited
9.26% · 18.25M sh
Maverick Capital, Ltd.
5.22% · 10.28M sh
Shin Nippon Biomedical Laboratories, Ltd.
4.88% · 9.61M sh
Driehaus Capital Management LLC
2.76% · 5.44M sh
PRIMECAP Management Company
2.72% · 5.35M sh
683 Capital Management, LLC
2.51% · 4.95M sh
FMR
2.50% · 4.92M sh
State Street Global Advisors
2.46% · 4.84M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 18 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 13.69% |
| Chandra Vargeese | CTO & Head of Platform Discovery Sciences | 0.17% |
| Gregory L. Verdine | Director | 0.13% |
| Kyle B. Moran | Chief Financial Officer | 0.03% |
| Heidi L. Wagner | Independent Director | 0.02% |
| Peter Kolchinsky | Independent Director | 0.01% |
| Aik Na Tan | Independent Director | 0.01% |
| Ken Takanashi | Independent Director | 0.01% |
| Paul B. Bolno | Chief Executive Officer | 0.01% |
| Erik Ingelsson | Chief Scientific Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-11 | Adrian George Rawcliffe | Independent Director | Automatic Disposition | -12,700 | $5.29 |
| 2026-08-10 | Ken Takanashi | Independent Director | Automatic Disposition | -3,864 | $6.01 |
| 2026-08-10 | Heidi L. Wagner | Independent Director | Derivative Exercise and Sale | -7,000 | $5.97–6.01 |
| 2026-08-10 | Aik Na Tan | Independent Director | Automatic Disposition | -432 | $6.01 |
| 2026-04-08 | Christopher I. Wright | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-08 | Erik Ingelsson | Chief Scientific Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-29 | RA Capital Management, L.P. | -- | Open Market Acquisition | +8,772,496 | $6.06–6.50 |
| 2026-03-22 | Shin Nippon Biomedical Laboratories, Ltd. | -- | Derivative Exercise and Retained | +3,901,348 | -- |
| 2026-02-25 | Christopher Francis | Senior VP of Corporate Development & Head of Emerging Areas | Derivative Exercise and Sale | -33,194 | $3.87–15.09 |
| 2026-02-08 | Chandra Vargeese | CTO & Head of Platform Discovery Sciences | Open Market Disposition | -3,228 | $13.45 |
| 2026-02-08 | Kyle B. Moran | Chief Financial Officer | Open Market Disposition | -3,588 | $13.45 |
| 2026-02-08 | Paul B. Bolno | Chief Executive Officer | Open Market Disposition | -10,480 | $13.45 |
| 2026-02-08 | Christopher Francis | Senior VP of Corporate Development & Head of Emerging Areas | Open Market Disposition | -1,883 | $13.45 |
| 2026-02-04 | Chandra Vargeese | CTO & Head of Platform Discovery Sciences | Other Acquisition | +45,625 | -- |
| 2026-02-04 | Chandra Vargeese | CTO & Head of Platform Discovery Sciences | Other Derivative Acquisition | +273,750 | $12.75 |
| 2026-02-04 | Kyle B. Moran | Chief Financial Officer | Other Acquisition | +45,625 | -- |
| 2026-02-04 | Kyle B. Moran | Chief Financial Officer | Other Derivative Acquisition | +273,750 | $12.75 |
| 2026-02-04 | Paul B. Bolno | Chief Executive Officer | Other Acquisition | +165,000 | -- |
| 2026-02-04 | Paul B. Bolno | Chief Executive Officer | Other Derivative Acquisition | +1,000,000 | $12.75 |
| 2026-02-04 | Christopher Francis | Senior VP of Corporate Development & Head of Emerging Areas | Other Acquisition | +38,750 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:02:42 · For reference only, not investment advice and not tailored to your situation.